Inflammatory mediators in autoimmune lacrimal gland disease in MRL/Mpj mice

Investigative Ophthalmology and Visual Science

Volumn 45, Issue 7, 2004, Pages 2293-2298

  Jabs, Douglas A ^a,b,e   Gérard, Hérvé C ^c   Wei, Yuewang ^d   Campbell, Adam L ^d   Hudson, Alan P ^c   Akpek, Esen Karamursel ^a   Lee, Bella ^a   Prendergast, Robert A ^a   Whittum Hudson, Judith A ^c,d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

^d WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INDUCIBLE NITRIC OXIDE SYNTHASE; MESSENGER RNA; NITRIC OXIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LACRIMAL GLAND DISEASE; MONONUCLEAR CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SJOEGREN SYNDROME; TISSUE INJURY;

ANIMALS; AUTOIMMUNE DISEASES; DISEASE MODELS, ANIMAL; IMMUNOENZYME TECHNIQUES; INFLAMMATION MEDIATORS; LACRIMAL APPARATUS; MICE; MICE, INBRED BALB C; MICE, INBRED MRL LPR; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SJOGREN'S SYNDROME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 3142618397     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.03-0958     Document Type: Article

References (34)

1. Jabs DA. Ocular manifestations of the rheumatic diseases. In: Tasman W, Jaeger EA, eds. Duane's Clinical Ophthalmology, Baltimore: Williams & Wilkins; 1992:1-40.
2. Jabs DA, Alexander EL, Green WR. Ocular inflammation in autoimmune MRL/Mp mice. Invest Ophthalmol Vis Sci. 1985;26:1223-1229.
3. Jabs DA, Prendergast RA. Murine models of Sjögren's syndrome: immunohistologic analysis of different strains. Invest Ophthalmol Vis Sci. 1988;29:1437-1443.
4. Jabs DA, Enger C, Prendergast RA. Murine models of Sjögren's syndrome: evolution of the lacrimal gland inflammatory lesions. Invest Ophthalmol Vis Sci. 1991;32:371-380.
5. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature. 1992;356:314-317.
6. Hayashi Y, Henyi N, Hamano H, Yangi K. Transfer of Sjögren's-like autoimmune lesions into SCID mice and prevention of lesions by anti-CD4 and anti-T cell receptor antibody treatment. Eur J Immunol. 1994;24:2826-2831.
7. Jabs DA, Prendergast RA. Reactive lymphocytes in lacrimal gland and renal vasculitic lesions of autoimmune MRL/lpr mice express L3T4. J Exp Med. 1987;166:1198-1203.
8. Jabs DA, Lee B, Whittum-Hudson JA, Prendergast RA. Th1 versus Th2 immune responses in autoimmune lacrimal gland disease in MRL/Mp mice. Invest Ophthalmol Vis Sci. 2000;41:826-831.
9. Jabs DA, Prendergast RA, Rorer EM, Hudson AP, Whittum-Hudson JA. Cytokines in autoimmune lacrimal gland disease in MRL/MpJ mice. Invest Ophthalmol Vis Sci. 2001;42:2567-2571.
10. Bogdan C. Nitric oxide and the regulation of gene expression. Cell Biol. 2001;11:66-75.
11. G-monomethyl-L-arginine. J Exp Med. 1994;179:651-660.
12. Chu CQ, Field M, Feldman M, Maini RN. Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum. 1991;34:1125-1132.
13. Finestein GS, Maki R, Alvano-Garcia JM. Quantitation analysis of cytokine gene expression in rheumatoid arthritis. J Immunol. 1990;144:2826-2831.
14. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000;343:1586-1593.
15. Lipsky PE, van der Heijde DM, St. Clair EW, et al. for the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group: infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med. 2000;343:1594-1602.
16. Baert F, Norman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003;348:601-608.
17. Sfikakis PP, Theodessidis PG, Kotsiari CG, Kaklamanis P, Mohomidelakis NN. Effect of infliximab on sight-threatening panuveitis in Behcet's disease. Lancet. 2001;358:295-296.
18. El-Shabrawi Y, Hermann J. Anti-tumor necrosis factor-alpha therapy with infliximab as an alternative to corticosteroids in the treatment of human leukocyte antigen B27-associated acute anterior uveitis. Ophthalmology. 2002;109:2342-2346.
19. Gerard HC, Branigan PJ, Schumacher HR, Hudson AP. Synovial chlamydia trachomatis in patients with reactive arthritis/Reiter's syndrome are viable but show aberrant gene expression. J Rheumatol. 1998;25:734-742.
20. Drescher KM, Whittum-Hudson JA. Herpes simplex virus type 1 alters transcript levels of tumor necrosis factor-alpha and interleukin-6 in retinal glial cells. Invest Ophthalmol Vis Sci. 1996;37:2302-2312.
21. Drescher KM, Whittum-Hudson JA. Evidence for induction of interferon-α and interferon-β in retinal glial cells of Müller. Virology. 1997;234:309-316.
22. Gerard HC, Wang Z, Whittum-Hudson JA, et al. Cytokine and chemokine mRNA produced in synovial tissue chronically-infected with Chlamydia trachomatis and C pneumoniae. J Rheumatol. 2002;29:1827-1835.
23. Hiratsuka M, Agatsuma Y, Mizugaki M. Rapid detection of CYP2C9*3 alleles by real-time fluorescence PCR based on SYBR Green. Mol Genet Metab. 1999;68:357-362.
24. Giulietti A, Overbergh L, Valckx D, et al. An overview of real-time quantitative PCR: applications to quantify cytokine gene expression. Methods. 2001;25:386-401.
25. Vilcek J, Lee TH. Tumor necrosis factor: new insights into the molecular mechanisms of its multiple actions. J Biol Chem. 1991;266:7313-7316.
26. Nathan C, Xie Q-W. Nitric oxide synthases: roles, tolls, and controls. Cell. 1994;78:915-918.
27. Snedecor GW, Cochran WG. Statistical Methods. 6th ed. Ames, IA: Iowa State University Press; 1967.
28. Clancy RM, Amin AR, Abramson SB. The role of nitric oxide in inflammation and immunity. Arthritis Rheum. 1998;41:1141-1151.
29. Jones LS, Rizzo LV, Agarwal RK, et al. IFN-γ deficient mice develop experimental autoimmune uveitis in the context of a deviant effector response. J Immunol. 1997;158:5997-6005.
30. Fox RI, Kang HI, Ando D, Abrams J, Pisa E. Cytokine mRNA expression in salivary gland biopsies of Sjögren's syndrome. J Immunol. 1994;152:5532-5539.
31. Ohyama Y, Nakamura S, Matsuzaki, G, et al. Cytokine messenger RNA expression in the labial salivary glands of patients with Sjögren's syndrome. Arthritis Rheum. 1996;39:1376-1384.
32. Aziz KE, Markovic B, McCluskey PJ, Wakefield D. A study of cytokines and minor salivary glands. In: Nussenblatt RB, Whitcup SM, Casbi RR, Gerry I, eds. Advances in Ocular Immunology. New York: Elsevier; 1994:303-306.
33. Bumba D, Skopouli FN, Moutsopoulos HM. Cytokine mRNA expression in the labial salivary gland tissues from patients with primary Sjogren's syndrome. Br J Rheumatol. 1995;34:326-333.
34. Steinfeld SD, Demols P, Salmon I, Kiss R, Appelboom T. Infliximab in patients with primary Sjögren's syndrome. Arthritis Rheum. 2001;44:2371-2375.